BlackRock Inc. Purchases Shares of 972,152 Apellis Pharmaceuticals (APLS)
BlackRock Inc. purchased a new position in shares of Apellis Pharmaceuticals (NASDAQ:APLS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 972,152 shares of the company’s stock, valued at approximately $21,096,000. BlackRock Inc. owned approximately 1.93% of Apellis Pharmaceuticals at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of APLS. The Manufacturers Life Insurance Company bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth $186,000. Quantitative Systematic Strategies LLC bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth $317,000. Bank of New York Mellon Corp bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth $416,000. Candriam Luxembourg S.C.A. bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth $2,539,000. Finally, NF Trinity Capital Hong Kong Ltd bought a new stake in Apellis Pharmaceuticals during the fourth quarter worth $7,750,000. 31.26% of the stock is currently owned by hedge funds and other institutional investors.
APLS has been the topic of several analyst reports. JPMorgan Chase upped their price target on shares of Apellis Pharmaceuticals from $31.00 to $35.00 and gave the stock an “overweight” rating in a research report on Friday, March 23rd. Zacks Investment Research lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. Finally, B. Riley lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, April 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $27.50.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Monday, March 19th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.33). equities research analysts anticipate that Apellis Pharmaceuticals will post -1.16 EPS for the current fiscal year.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Want to see what other hedge funds are holding APLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apellis Pharmaceuticals (NASDAQ:APLS).
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.